Ca-channel blockers and oral anticoagulation
Aromatorio, G. J., Uretsky, B. F. and Reddy, P. S. (1985) Hypotension and sinus arrest with nifedipine in pulmonary hypertension. Chest, 87, 265-267.
Bärtsch, P., Maggiorini, M., Ritter, M., et al. (1991) Prevention of high altitude pulmonary edema by nifedipine. N Engl J Med, 325, 1284-1289.
Batra, A. K., Segall, P. H. and Ahmed, T. (1985) Pulmonary edema with nifedipine in primary pulmonary hypertension. Respiration, 47, 161-163.
Chaouat, A., Kessler, R. and Weitzenblum, E. (1996) Pulmonary oedema and pleural effusion in two patients with primary pulmonary hypertension treated with calcium channel blockers. Heart, 75, 383.
Cohen, M., Edwards, W. D. and Fuster, V. (1986) Regression in thromboembolic type of primary pulmonary hypertension during 2 1/2 years of antithrombotic therapy. J Am Coll Cardiol, 7, 172-175.
Farber, H. W., Karlinsky, J. B. and Faling, L. J. (1983) Fatal outcome following nifedipine for pulmonary hypertension. Chest, 83, 708-709.
Frank, H., Gurtner, H. P., Kneussl, M., et al. (1993) Aminorex-induced, plexogenic pulmonary arteriopathy: 25 years later! Z Kardiol, 82, 568-572.
Fuster, V., Steele, P. M., Edwards, W. D., et al. (1984) Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation, 70, 580-587.
Hackett, P. H., Roach, R. C., Hartig, G. S., et al. (1992) The effect of vasodilators on pulmonary hemodynamics in high altitude pulmonary edema: A comparison. Int J Sports Med, 13 (Suppl 1), S68-S71.
Hoeper, M. M., Olschewski, H., Ghofrani, H. A., et al. (2000) A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH study group. J Am Coll Cardiol, 35, 176-182.
Hohenhaus, E., Niroomand, F., Görre, S., et al. (1995) Nifedipine dos not prevent acute mountain sickness. Am J Respir Crit Care Med, 150, 857-860.
Morgan, J. M., McCormack, D. G., Griffiths, M. J., et al. (1991) Adenosine as a vasodilator in primary pulmonary hypertension. Circulation, 84, 1145-1149.
Moser, K. M., Fedullo, P. F., Finkbeiner, W. E., et al. (1995) Do patients with primary pulmonary hypertension develop extensive central thrombi? Circulation, 91, 741-745.
Oelz, O., Maggiorini, M., Ritter, M., et al. (1989) Nifedipine for high altitude pulmonary oedema. Lancet, 2 (8674), 1241-1244.
Olschewski, H., Walmrath, D., Schermuly, R., et al. (1996) Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med, 124, 820-824.
Packer, M., Medina, N. and Yushak, M. (1984) Adverse hemodynamic and clinical effects of calcium channel blockade in pulmonary hypertension secondary to obliterative pulmonary vascular disease. J Am Coll Cardiol, 4, 890-901.
Partanen, J., Nieminen, M. S. and Luomanmaki, K. (1993) Death in a patient with primary pulmonary hypertension after 20 mg of nifedipine. N Engl J Med, 329, 812; discussion 812-813.
Prigogine, T., Waterlot, Y., Gottignies, P., et al. (1991) Acute nonhemodynamic pulmonary edema with nifedipine in primary pulmonary hypertension. Chest, 100, 563-564.
Rich, S. and Brundage, B. H. (1987) High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy. Circulation, 76, 135-141.
Rich, S., Ganz, R. and Levy, P. S. (1983) Comparative actions of hydralazine, nifedipine and amrinone in primary pulmonary hypertension. Am J Cardiol, 52, 1104-1107.
Rich, S. and Kaufmann, E. (1991) High dose titration of calcium channel blocking agents for primary pulmonary hypertension: guidelines for short-term drug testing. J Am Coll Cardiol, 18, 1323-1327.
Rich, S., Kaufmann, E. and Levy, P. S. (1992) The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med, 327, 76-81.
Rubin, L. J., Groves, B. M., Reeves, J. T., et al. (1982) Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension. Circulation, 66, 334-338.
Rubin, L. J., Nicod, P., Hillis, L. D., et al. (1983) Treatment of primary pulmonary hypertension with nifedipine. A hemodynamic and scintigraphic evaluation. Ann Intern Med, 99, 433-438.
Sitbon, O., Humbert, M., Jagot, J. L., et al. (1998) Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. Eur Respir J, 12, 265-270.
Weir, E. K., Rubin, L. J., Ayres, S. M., et al. (1989) The acute administration of vasodilators in primary pulmonary hypertension. Experience from the National Institutes of Health Registry on Primary Pulmonary Hypertension. Am Rev Respir Dis, 140, 1623-1630.
Bärtsch, P., Maggiorini, M., Ritter, M., et al. (1991) Prevention of high altitude pulmonary edema by nifedipine. N Engl J Med, 325, 1284-1289.
Batra, A. K., Segall, P. H. and Ahmed, T. (1985) Pulmonary edema with nifedipine in primary pulmonary hypertension. Respiration, 47, 161-163.
Chaouat, A., Kessler, R. and Weitzenblum, E. (1996) Pulmonary oedema and pleural effusion in two patients with primary pulmonary hypertension treated with calcium channel blockers. Heart, 75, 383.
Cohen, M., Edwards, W. D. and Fuster, V. (1986) Regression in thromboembolic type of primary pulmonary hypertension during 2 1/2 years of antithrombotic therapy. J Am Coll Cardiol, 7, 172-175.
Farber, H. W., Karlinsky, J. B. and Faling, L. J. (1983) Fatal outcome following nifedipine for pulmonary hypertension. Chest, 83, 708-709.
Frank, H., Gurtner, H. P., Kneussl, M., et al. (1993) Aminorex-induced, plexogenic pulmonary arteriopathy: 25 years later! Z Kardiol, 82, 568-572.
Fuster, V., Steele, P. M., Edwards, W. D., et al. (1984) Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation, 70, 580-587.
Hackett, P. H., Roach, R. C., Hartig, G. S., et al. (1992) The effect of vasodilators on pulmonary hemodynamics in high altitude pulmonary edema: A comparison. Int J Sports Med, 13 (Suppl 1), S68-S71.
Hoeper, M. M., Olschewski, H., Ghofrani, H. A., et al. (2000) A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH study group. J Am Coll Cardiol, 35, 176-182.
Hohenhaus, E., Niroomand, F., Görre, S., et al. (1995) Nifedipine dos not prevent acute mountain sickness. Am J Respir Crit Care Med, 150, 857-860.
Morgan, J. M., McCormack, D. G., Griffiths, M. J., et al. (1991) Adenosine as a vasodilator in primary pulmonary hypertension. Circulation, 84, 1145-1149.
Moser, K. M., Fedullo, P. F., Finkbeiner, W. E., et al. (1995) Do patients with primary pulmonary hypertension develop extensive central thrombi? Circulation, 91, 741-745.
Oelz, O., Maggiorini, M., Ritter, M., et al. (1989) Nifedipine for high altitude pulmonary oedema. Lancet, 2 (8674), 1241-1244.
Olschewski, H., Walmrath, D., Schermuly, R., et al. (1996) Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med, 124, 820-824.
Packer, M., Medina, N. and Yushak, M. (1984) Adverse hemodynamic and clinical effects of calcium channel blockade in pulmonary hypertension secondary to obliterative pulmonary vascular disease. J Am Coll Cardiol, 4, 890-901.
Partanen, J., Nieminen, M. S. and Luomanmaki, K. (1993) Death in a patient with primary pulmonary hypertension after 20 mg of nifedipine. N Engl J Med, 329, 812; discussion 812-813.
Prigogine, T., Waterlot, Y., Gottignies, P., et al. (1991) Acute nonhemodynamic pulmonary edema with nifedipine in primary pulmonary hypertension. Chest, 100, 563-564.
Rich, S. and Brundage, B. H. (1987) High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy. Circulation, 76, 135-141.
Rich, S., Ganz, R. and Levy, P. S. (1983) Comparative actions of hydralazine, nifedipine and amrinone in primary pulmonary hypertension. Am J Cardiol, 52, 1104-1107.
Rich, S. and Kaufmann, E. (1991) High dose titration of calcium channel blocking agents for primary pulmonary hypertension: guidelines for short-term drug testing. J Am Coll Cardiol, 18, 1323-1327.
Rich, S., Kaufmann, E. and Levy, P. S. (1992) The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med, 327, 76-81.
Rubin, L. J., Groves, B. M., Reeves, J. T., et al. (1982) Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension. Circulation, 66, 334-338.
Rubin, L. J., Nicod, P., Hillis, L. D., et al. (1983) Treatment of primary pulmonary hypertension with nifedipine. A hemodynamic and scintigraphic evaluation. Ann Intern Med, 99, 433-438.
Sitbon, O., Humbert, M., Jagot, J. L., et al. (1998) Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. Eur Respir J, 12, 265-270.
Weir, E. K., Rubin, L. J., Ayres, S. M., et al. (1989) The acute administration of vasodilators in primary pulmonary hypertension. Experience from the National Institutes of Health Registry on Primary Pulmonary Hypertension. Am Rev Respir Dis, 140, 1623-1630.
Druckversion
Suche
SGPH-Symposium, 2. September 2010, Hotel Bristol in Genf:
"Hypertension artérielle pulmonaire: Comment ne pas passer à côté d’une maladie émergente?" Mehr
Umfrage:
Helfen Sie uns, den Bereich "Patienten" weiter zu verbessern und Ihren Ansprüchen anzupassen indem Sie an unserer Umfrage teilnehmen.
Vereinsgründung:
Schweizer PH-Verein für Menschen mit pulmonaler Hypertonie gegründet. Pressemitteilung PDF
Next SSPH Workshop: October 28th, 2010
Haus der Universität in Berne, details will follow.
SSPH Workshop 2010: May 7-8, 2010
The SSPH workshop on May 7-8, 2010 in Lucerne did consist of an update of the website with the following topics:
- Diagnosis
- Treatment
- Follow-up
- Patients part
4th international Congress of the SSPH
October 30 - 31, 2009
Link to the congress presentations as video streaming on swiss-webconferencing.ch .
Link to the congress photo-gallery
mehr